p53 Autoantibodies in Patients with Autoimmune Diseases: A Quantitative Approach

With few exceptions, autoantibodies directed against the gene product of the tumor suppressor gene p53 are only detected in cancer patients. From 73 patients with various autoimmune diseases, we obtained 17 sera with elevated autoantibodies against the p53 protein comprising patients with SLE, Grave...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity (Chur, Switzerland) Switzerland), 1999-01, Vol.31 (3), p.229-235
Main Authors: Kuhn, Hella-Monika, Kromminga, Arno, Flammann, Heiko T., Frey, Manfred, Layer, Peter, Arndt, Rüdiger
Format: Article
Language:English
Subjects:
Antibody levels
Autoantibodies - blood
Autoimmune diseases
Autoimmune Diseases - blood
Biological and medical sciences
Female
General aspects
Granulomatosis with Polyangiitis - blood
Graves Disease - blood
Humans
Immunopathology
Lupus Erythematosus, Systemic - blood
Male
Medical sciences
Middle Aged
Neoplasms - blood
Neoplasms - immunology
p53 autoantibodies
p53 protein
Tumor Suppressor Protein p53 - immunology
Vasculitis - blood
Vasculitis - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With few exceptions, autoantibodies directed against the gene product of the tumor suppressor gene p53 are only detected in cancer patients. From 73 patients with various autoimmune diseases, we obtained 17 sera with elevated autoantibodies against the p53 protein comprising patients with SLE, Graves' disease, and immune vasculitis including Wegener's granulomatosis. The overall prevalence (23%) of p53 autoantibodies was comparable to that in various cancers; differences, however, were obvious with respect to the magnitude of antibody levels. Only 5% of seropositive colorectal cancer patients had levels within the critical range (150-180 U/ml) but nearly half (41%) of seropositive autoimmune disease patients were that low. None of the autoimmune disease patients exceeded 300 U/ml serum compared to more than 60% of seropositive colorectal cancer patients with higher levels. This remarkable difference in magnitude underlines the necessity of quantification of p53 autoantibodies over a mere qualitative determination. Patients with autoimmune diseases face an increased risk for malignancies. It still remains to be established whether p53 seropositivity in autoimmune diseases adds to the rare exceptions of p53AAb in non-malignant diseases or is indicative for a yet occult cancer.
ISSN:0891-6934
1607-842X
DOI:10.3109/08916939908994068